Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 11 Sep - Newspaper Publication regarding 3rd and 4th reminder for special window for re-lodgement of transfer requests of physical shares
Source: Bse
Albert David Limited (ALBERTDAVD)
Small CapPharma stocks · Small cap · NSE
Albert David Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 04:45 am ISTDetails
Quote21 Oct, 04:45 am IST
Base fundamentals05 Oct 2026 · screener
Latest result16 Aug, 12:57 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags03 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
67BullishSMA20 -3.6% / mo · MACD − · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 46
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
ALBERTDAVDD candles · FIT view+14.4%Latest close ₹797.75 on 2026-10-19
Bar
-4.9%
RSI
44
MACD hist
-4.03
52W pos
62%
2026-10-19O ₹838.95H ₹838.95L ₹793.00C ₹797.75Vol 2,510 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
ALBERTDAVDNifty PharmaNifty 500
- ALBERTDAVD
- +14.3%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- +19.9 pp
Chart stats
19 Oct 2026- From 52W high
- -14.4%
- 52W range position
- 62%
- ATR (14)
- 3.9%
- Volume vs 20D
- 0.60x
- Avg traded value
- ₹0.4 Cr
- 20D price channel
- ₹774.7 - ₹898
₹931.9
₹579.9 - ₹931.9
₹31.4
Latest completed session
20-session average
40.2% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · OVERVALUED26
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent100
Revenue +42.3% · PAT +300.0% YoY
Technical
Bullish67
Price trend and sector-relative-strength timing.
Valuation
Legacy model-23.0%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence60
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 100/100Rev +42% YoY · PAT +300% YoY · margin expansion · +17% QoQ · operating leverage
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹101 Cr | +42.3% | +17.4% |
| EBITDA | ₹11 Cr | +200.0% | +266.7% |
| Operating margin | 10.0% | +2500 bps | +680 bps |
| PAT | ₹32 Cr | +300.0% | NDF |
| PAT margin | 31.7% | +2041 bps | +5610 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 21.70
- P/B
- 1.25
- EV/EBITDA
- 14.03
- Market Cap
- 489.00Cr
Profitability
- ROE
- -0.44%
- ROCE
- 0.82%
- ROA
- 4.43%
- Dividend Y
- 0.58%
Growth (CAGR)
- Revenue 5Y
- 6.00%
- EPS 5Y
- 7.00%
- Revenue 3Y
- -1.00%
- EPS 3Y
- 1.00%
Balance Sheet
- Debt/Equity
- 0.08
- Interest Coverage
- 9.00×
- Altman Z
- 4.50
- Book Value
- 686.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 7/5
- OCF
- -8.00 Cr
- EPS TTM
- 39.55
Shareholding
- Promoter Hold
- 62.23%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 79%
Financial History
Updated 19/10/2026
Revenue
₹ CrLatest: 101+17.4% vs prev
Net Profit
₹ CrLatest: 32.0+252.4% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 44. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~3.8% over last month) — short-term momentum negative.
- RSI(14) at 44 — rising, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- 14% off 52W high · 38% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
67
RS percentile
Stage 2 UptrendEstablished S2
1M return
-4.3%
3M return
+14.3%
6M return
+7.4%
1Y return
-4.8%
RS 1D
-4
RS 20D
-2
Sector rank
#1
Industry rank
#11
Stage evidence
- Price is 6.4% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +2.6%.
- Both 3-month and 6-month returns are positive.
50-DMA
price below
200-DMA
price above
S2 entered
20 Aug 2026
S2 age
41 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 105.88-3.00%
RS vs Nifty 500106
Valuation & peers
U-Score 26 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 26 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation7/30
Growth5/25
Quality0/20
Balance Sheet13/15
Cash Flow3/10
Piotroski
4/9 (+1)
Penalties
-3
Raw sum
26
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
26/100 · legacy band OVERVALUED
Positive drivers
- Balance sheet contributes 13/15 to the score.
- Cash flow contributes 3/10 to the score.
- Valuation contributes 7/30 to the score.
Main drags
- Penalty bucket subtracts 3 points.
- Fair-value margin of safety is negative at -23.0%.
- Quality is weaker at 0/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
21.7
PB
1.3
EV/EBITDA
14.0
ROE
-0.4%
ROCE
0.8%
FCF Yield
—
Debt/Equity
0.1
MoS
-23.0%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
26
Previous: 26
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
-23.0%
Previous: -23.0%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
26
26
26
27
26
26
26
26
26
26
26
26
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹781.32
-2.1% MoS
Growth-justified P/E
16.4
Growth-justified Value
₹648.62
-23.0% MoS
PEG
4.72
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
HALEOSLABS
Small
HALEOS LABS LIMITED
Pharmaceuticals
match 167
29
29.6
8.4%
-139%
OVERVALUED
MEDICAMEQ
Small
Medicamen Biotech Limited
Pharmaceuticals
match 166
18
38.9
4.0%
-521%
OVERVALUED
AAREYDRUGS
Small
Aarey Drugs & Pharmaceuticals Limited
Pharmaceuticals
match 164
15
79.4
2.8%
-1817%
OVERVALUED
AMBALALSA
Small
Ambalal Sarabhai Enterprises Limited
Pharmaceuticals
match 163
41
20.4
12.4%
+30%
WATCHLIST
AMANTA
Small
Amanta Healthcare Limited
Pharmaceuticals
match 162
39
48.2
10.3%
+3%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Albert David Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
60Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 28th percentile of the scored universe and 19th percentile within Pharma. Main check: results consistency is weak at 29/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
5 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
28th percentile
overall median 67 · Pharma: 19th pctile, median 70 · Small: 32nd pctile, median 66
Evidence depth
Financial-only
5 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
52
watch · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
30
weak · capital discipline
Results
29
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 62.2%.
- ▸Promoter pledge is zero.
- ▸7 years of positive FCF.
- ▸Debt/equity is 0.08.
Trust risks
- ▸Operating cash flow is negative at ₹-8 Cr.
- ▸3 latest quarters had PAT decline worse than 25% YoY.
- ▸ROCE is low at 0.8%.
- ▸ROE is low at -0.4%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Albert David Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Change in Management 6 Aug - Dr. Kuntal Ganguly resigned as Head-R&D effective 5 August 2026.
Source: Bse
Annual reportAug 2026
Aug 2026 · Pursuant To Regulation 36(1)(B) Of SEBI Listing Regulations, 2015, The Company Has Completed The Dispatch Of The Letters Containing The Web-Link Of The Annual Report To Those Members Whose Email Address(Es) Were Not Registered With The Company/Depository(Ies). 15 Jul - Annual report web-links dispatched to 1,116 members; 87th AGM on 6 August 2026.
Source: Bse
Annual reportAug 2026
Aug 2026 · Reg. 34 (1) Annual Report. 13 Jul - 87th AGM on 6 Aug 2026; record date 30 Jul, e-voting 3-5 Aug.
Source: Bse
AnnouncementAug 2026
Aug 2026 · KMP''s Authorised To Determine Materiality Under Regulation 30(5) Of SEBI(LODR),2015 12 May - Board appointed Amit Mahla CEO, approved FY26 results, recommended Rs5 final dividend, AGM on 6 Aug 2026.
Source: Bse
AnnouncementJul 2026
Jul 2026 · Announcement under Regulation 30 (LODR)-Change in Management 4 Jul - Cluster-Head Saikath Banerjee resigned effective July 4, 2026, due to personal reasons.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 2 Jul - Enclosed herewith copy of Newspaper Publication regarding Notice issued for attention of the shareholders in respect of information regarding 87th Annual General Meeting scheduled to …
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 7 Aug - Newspaper Publication regarding extract of unaudited financial results for the first quarter ended 30th June, 2026
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Change in Management 19 Jun - Board appointed Amit Mahla as Additional Director and Whole-time Director & CEO for 5 years from June 19, 2026.
Source: Bse
Credit rating
Announcement under Regulation 30 (LODR)-Credit Rating 26 Jun - CARE reaffirmed Albert David’s ratings: ₹50.5 crore long-term A/Negative and ₹12 crore mixed A/Negative, A1.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 18 Jun - Disclosure pursuant to Reg. 30 - Publication of Notice in Newspapers for transfer of equity shares of the Company to the Investor Education and Protection …
Source: Bse
AnnouncementMay 2026
May 2026 · Announcement under Regulation 30 (LODR)-Change in Management 30 May - Head-Operations, Ghaziabad Plant, Chandra Bhushan Thakur resigned effective 29 May 2026.
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.